- Home
- CPAC vs URGN Comparison
CPAC vs URGN Comparison
Compare CPAC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPAC
- URGN
- Stock Information
- Founded
- CPAC 1949
- URGN 2004
- Country
- CPAC Peru
- URGN United States
- Employees
- CPAC N/A
- URGN N/A
- Industry
- CPAC Building Materials
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CPAC Industrials
- URGN Health Care
- Exchange
- CPAC Nasdaq
- URGN Nasdaq
- Market Cap
- CPAC 436.7M
- URGN 463.2M
- IPO Year
- CPAC 2012
- URGN 2017
- Fundamental
- Price
- CPAC $5.54
- URGN $10.67
- Analyst Decision
- CPAC Sell
- URGN Strong Buy
- Analyst Count
- CPAC 1
- URGN 7
- Target Price
- CPAC $6.00
- URGN $36.75
- AVG Volume (30 Days)
- CPAC 7.6K
- URGN 662.5K
- Earning Date
- CPAC 04-28-2025
- URGN 05-12-2025
- Dividend Yield
- CPAC 9.05%
- URGN N/A
- EPS Growth
- CPAC 15.59
- URGN N/A
- EPS
- CPAC 0.13
- URGN N/A
- Revenue
- CPAC $545,786,617.00
- URGN $90,398,000.00
- Revenue This Year
- CPAC N/A
- URGN $36.82
- Revenue Next Year
- CPAC N/A
- URGN $119.10
- P/E Ratio
- CPAC $8.70
- URGN N/A
- Revenue Growth
- CPAC 2.78
- URGN 9.29
- 52 Week Low
- CPAC $5.10
- URGN $8.94
- 52 Week High
- CPAC $6.65
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- CPAC 50.73
- URGN 50.74
- Support Level
- CPAC $5.20
- URGN $9.63
- Resistance Level
- CPAC $5.59
- URGN $11.75
- Average True Range (ATR)
- CPAC 0.14
- URGN 0.82
- MACD
- CPAC 0.02
- URGN -0.00
- Stochastic Oscillator
- CPAC 70.83
- URGN 51.17
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that primarily produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are primarily used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.